OAOmolola Adenike Ajayi-Odoko

Omolola Adenike Ajayi-Odoko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Omolola Adenike Ajayi-Odoko has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Occurrence of Carbapenemase Resistance genes in hospital wastewater from selected facilities in Ibadan, Oyo State, Nigeria

    by Omolola Adenike Ajayi-Odoko, Ayantade Dayo Victor Ayansina, Emmanuel Adewuni Akintunde, Iyinkristi Damilare Ayokunle, Wuraola Omolola Ibitoye, Adewale Oluropo Olatayo

  • Open Access

    Bioprospection of indigenous herbal formulations for diabetes care: in vitro, network pharmacology, and molecular dynamics studies

    by Oluwafemi Adeleke Ojo, Akingbolabo Daniel Ogunlakin, Omolola Adenike Ajayi-Odoko, Gideon Ampoma Gyebi, Damilare IyinKristi Ayokunle, Adesoji Alani Olanrewaju, Oluwatobi Deborah Agbeye, Emmanuel Tope Ogunwale, Oluyomi Stephen Adeyemi

    Herbal formulations have garnered significant interest from researchers for their potential antidiabetic effects. However, scientific validation of their efficacy and understanding of their mechanisms of action have limited their use in modern medicine. Therefore, we investigated crude formulations consisting of Beta vulgaris leaves, Persea americana seeds, Beta vulgaris roots and Syzygium aromaticum for the management of type 2 diabetes mellitus (T2DM) by combining network pharmacology with experimental verification. We screened 11 active ingredients and 3238 corresponding targets from biological databases. Additionally, the stability of the top-ranked poses and positive compounds linked to DPP-IV, α-amylase, and α-glucosidase were evaluated via molecular dynamics. Herbal formulations Formulations A and B exhibited notable inhibitory activity against the α-amylase enzyme, with IC50 values of 113.325. ± 6.627 and 170.704 ± 5.658 µg/mL, respectively, compared with that of acarbose (IC50 = 27.704 ± 0.270 µg/mL). Notably, Formulation B (IC50 = 15.035 ± 4.582 µg/mL) exhibited greater inhibitory activity than both Formulation A (IC50 = 271.835 ± 5.601 µg/mL) and the standard acarbose (IC50 = 17.389 ± 0.436 µg/mL). In addition, both Forms A (IC50 = 150.953 ± 23.127 µg/mL) and B (IC50 = 194.706 ± 37.776 µg/mL) showed notable inhibitory activity against DPP-IV compared with the standard evogliptin (IC50 = 86.534 ± 6.043 µg/mL). Furthermore, neither crude formulation exhibited cellular toxicity in human foreskin fibroblasts, with IC50 values for formulation A (1949 µg/mL) being lower than those for formulation B (7580 µg/mL). On the basis of our findings, the main active components, namely, quercetrin, rutin, and myricetin, exhibit strong binding affinities and stability for DPP-IV, α-amylase, and α-glucosidase. According to the results of the GO and KEGG analyses, the use of crude formulations to treat T2D may affect various pathways, including the EGFR and PI3K/Akt pathways. These results provide a scientific and experimental foundation for the use of these particular plants for the treatment of T2D.


  • Open Access

    Network Pharmacology, Molecular Dynamics and In Vitro Assessments of Indigenous Herbal Formulations for Alzheimer’s Therapy

    by Oluwafemi Adeleke Ojo, Omolola Adenike Ajayi-Odoko, Gideon Ampoma Gyebi, Damilare IyinKristi Ayokunle, Akingbolabo Daniel Ogunlakin, Emmanuel Henry Ezenabor, Adesoji Alani Olanrewaju, Oluwatobi Deborah Agbeye, Emmanuel Tope Ogunwale, Damilare Emmanuel Rotimi, et al.

    Alzheimer’s disease (AD) is an age-associated neurodegenerative condition marked by amyloid plaques, synaptic dysfunction, and neuronal loss. Besides conventional medical care, herbal therapies, both raw and refined, have attracted researchers for their potential therapeutic effects. As a proof-of-concept, our study combined HPLC-DAD analysis of bioactive constituents, network pharmacology, molecular dynamics (MD), molecular docking, post-MD analysis, and experimental verification to investigate the mechanisms of crude drug formulations as a therapeutic strategy for AD. We identified nine bioactive compounds targeting 188 proteins and 1171 AD-associated genes. Using a Venn diagram, we found 47 overlapping targets, forming “herb-compound-target (HCT)” interaction networks and a protein‒protein interaction (PPI) network. Simulations analyzed binding interactions among the three core targets and their compounds. MD assessed the stability of the best-ranked poses and beneficial compounds for each protein. Among the top 22 hub genes, AChE, BChE, and MAO, ranked 10, 14, and 34, respectively, were selected for further analysis. Two tetraherbal formulations, Form A and Form B, showed notable activity against AChE. Form A exhibited significant (p < 0.0001) inhibitory activity (IC50 = 114.842 ± 2.084 µg/mL) compared to Form B (IC50 = 142.829 ± 4.258 µg/mL), though weaker than galantamine (IC50 = 27.950 ± 0.122 µg/mL). Form B had significant inhibitory effects on BChE (IC50 = 655.860 ± 32.812 µg/mL) compared to Form A (IC50 = 679.718 ± 20.656 µg/mL), but lower than galantamine (IC50 = 23.126 ± 0.683 µg/mL). Both forms protected against Fe2+-mediated brain injury by inhibiting MAO. Docking identified quercetin (−10.2 kcal/mol) and myricetin (−10.1 kcal/mol) for AChE; rutin (−10.6 kcal/mol) and quercetin (−9.7 kcal/mol) for BChE; and kaempferol (−9.1 kcal/mol) and quercetin (−8.9 kcal/mol) for MAO. These compounds were thermodynamically stable based on MD analysis. Collectively, the results offer a scientific rationale for the use of these specifically selected medicinal herbs as AD medications.


  • Open Access

    Artocarpus Communis Seed Regulates P53, IRS, HsD17β2, FTO, and CYP11a Genes in Polycystic Ovarian Syndrome Rats

    by Akingbolabo Daniel Ogunlakin, Oluwafemi Adeleke Ojo, Chimzi David Onu-Boms, Oluwafemi Samson Afolayan, Peluola Olujide Ayeni, Idayat Adeola Akinwumi, Opeyemi Josephine Akinmurele, Great Oluwamayokun Adebodun, Damilare Iyinkristi Ayokunle, Owoola Azeezat Ambali, et al.

    Polycystic ovarian syndrome (PCOS) is a prevalent endocrine illness that affects 5-10% of reproductive women globally. It is a multifaceted hormonal disorder characterized by the involvement of numerous molecular mechanisms that contribute to its development. This study investigates the effect of Artocarpus communis seed on the hormonal imbalance and P53, IRS, HsD17β2, FTO, and CYP11a genes expression in the ovaries of letrozole-induced polycystic ovarian syndrome rats. To induce PCOS in 30 female Wistar rats, letrozole was administered at a dosage of 1 mg/kg. For 12 days, Artocarpus communis seed aqueous extract (100 and 250 mg/kg body weight) and Clomiphene citrate (1 mg/kg body weight), a standard medication, were given. ELISA assessed luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol levels. The levels of P53, IRS, HsD17β2, FTO, and CYP11a gene expression in the ovaries were assessed. The aqueous extract reduced LH and increased FSH levels in Letrozole-induced PCOS rats. Additionally, seed aqueous extract (250 mg/kg bw) regulated the expression of P53, type 2 17-HSD (17-HSD), fat mass and obesity-associated (FTO), 11a-hydroxylase/17,20-desmolase (CYP11a), and insulin receptor substrate (IRS) genes in the ovaries of PCOS rats. Therefore, Artocarpus communis seed might have multifaceted effects on molecular pathways associated with PCOS, potentially normalizing androgen metabolism, hormonal imbalance, and ovarian function.


  • Open Access

    Occurrence of Extended Spectrum Beta Lactamase (ESBL) Producing Gram-Negative Bacteria in Wastewaters from Selected Hospitals in Ibadan, Oyo State, Nigeria

    by Ajayi-Odoko O. Adenike, Dayo A. Ayansina

    As an environmental antimicrobial resistance reservoir, untreated hospital wastewater plays a crucial role in the spread of antibiotic-resistant genes. The goal of this study was to look at the genetic drivers of ESBL resistance in Gram-negative bacteria isolates from hospital wastewater in Ibadan, Nigeria. A total of 408 bacterial isolates were obtained, with 54 being chosen for Polymerase Chain Reaction (PCR) testing due to resistance to more than three antibiotic classes. All the fifty-four ESBL producers were resistant to ceftazidime, while 40 (74.07%) showed resistance to cefotaxime. Percentage resistance to azithromycin, sulfamethoxazole trimethoprim, cefotaxime and streptomycin was 59.26 %, 64.81%, 74.07% and 75.93% respectively. Twenty seven of the ESBL- producing isolates representing 50.00 % was resistant to oxacillin. Moreover, percentage resistance to ciprofloxacin and cefepime was 38.89% and 31.48% respectively. BlaTEM-1 had the highest percentage frequency of occurrence of 85.19% while blaCTX-M had the least value of 7.41%. The percentage occurrence for resistant gene blaSHV-2, and blaSHV-1, was 20.37%, and 5.56% respectively. The presence of ESBL bacteria in hospital wastewater shows the role played by the discharge of untreated hospital wastewater in the horizontal spread of antibiotic resistance genes. As a result, Nigeria's tradition of discharging untreated hospital effluent into the environment poses a serious threat to public health.